

Steven P. Jones, PhD
Professor of Medicine and University Scholar
Director, Center for Cardiometabolic Science

Center for Cardiometabolic Science
Christina Lee Brown Envirome Institute
University of Louisville School of Medicine
580 South Preston Street
Delia Baxter Building, Room 421
Louisville, KY, 40202
Office: 502-852-2460

Email: Steven.P.Jones@Louisville.edu Twitter: [@StevenPJones](https://twitter.com/StevenPJones)

EDUCATION

1996 BS in Biology, Louisiana State University, Shreveport, LA
2002 PhD in Physiology, Louisiana State University Health Sciences Center, Shreveport, LA
2004 Postdoctoral Fellowship, Johns Hopkins University School of Medicine, Baltimore, MD

ACADEMIC APPOINTMENTS

2004–2009 **Assistant Professor.** Department of Medicine, University of Louisville, Louisville, KY
2009–2015 **Associate Professor.** Department of Medicine, University of Louisville, Louisville, KY (Tenured in 2010)
2015–pres. **Professor** (associate appt. in Physiology; Pharmacology & Toxicology). Department of Medicine, University of Louisville, Louisville, KY
2019–pres. **Director.** Center for Cardiometabolic Science. Department of Medicine, Division of Environmental Medicine, University of Louisville, Louisville, KY

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

Memberships

American Physiological Society (Cardiovascular Section)
American Heart Association (Basic Cardiovascular Sciences Council)
International Society for Heart Research
American Society of Pharmacology & Experimental Therapeutics (CVP Section)

HONORS AND AWARDS

As trainee:

2001 APS Proctor & Gamble Professional Opportunity Award (CV Section)
2001 APS Caroline tum Suden/Frances A. Hellebrandt Award
2001 Edward S. Reynolds Memorial Pathology Award (NSRF)
2001 American Medical Association Overall Excellence in Research (NSRF)
2002 American Heart Association Postdoctoral Fellow Abstract Award

- 2002 Louisiana State University Health Sciences Center Chancellor's Award
- 2002 ASPET Graduate Student Best Paper Award—2nd Place (CV section)
- 2003 ASPET Postdoctoral Fellow Best Paper Award—1st Place (CV section)

As faculty:

- 2009 "Reviewer of the Year" for *Circulation Research*
- 2010 "University Scholar" designation—University of Louisville
- 2011 "Top Cited Article (2006-2010)" in *Journal of Molecular and Cellular Cardiology*
- 2011 Fellow, American Physiological Society—Cardiovascular Section
- 2012 "Circle of Excellence Award" for Leadership and Professionalism—LSU-Shreveport
- 2012 Member, Southern Society for Clinical Investigation
- 2013 Fellow, American Heart Association (Basic Cardiovascular Sciences Council)
- 2018 "Outstanding Investigator Award", International Society for Heart Research
- 2018 Chair, "Myocardial Ischemia and Metabolism" — NIH Scientific Review Group
- 2022 Fellow, International Society for Heart Research
- 2022 Finalist, University of Louisville School of Medicine's Faculty Excellence Awards for Outstanding Research in the Basic and Applied Sciences
- 2023 Finalist, University of Louisville's Presidential Distinguished Outstanding Scholarship, Research, and Creative Activity in Basic & Applied Sciences Award

COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICE

Extramural Activities:

National Institutes of Health:

- 2009 ZHL1 CCT-I (C3) NHLBI Proteomic Centers – *ad hoc* reviewer
- 2009 ZRG1 CVRS-F (02) M Cardiac Energetics – *ad hoc* reviewer
- 2009 ZHL1 CSR-A (01) NHLBI Grand Opportunities in Phase II Clinical Trials (ARRA)
- 2009 Program Project Grant Review Panel – *ad hoc* reviewer
- 2010 ZRG1 CVRS-F (02) M Cardiac Energetics – *ad hoc* reviewer
- 2011 RFA HL-12-009 – "Anchoring Metabolomic Changes to Phenotype (P20)"
- 2011 SEP/SRG 2011/05 ZRG1 CVRS-B (02) – *ad hoc* reviewer (round one)
- 2012 SBIR/ZRG1 CVRS-N (10) – *ad hoc* reviewer
- 2012 SEP/ZRG1 CVRS-F (02) – *ad hoc* reviewer
- 2012 SEP/Member conflicts NHLBI (for MIM/CICS) – *ad hoc* reviewer
- 2013 SEP/ZRG1 CVRS-K (02) M – *ad hoc* reviewer
- 2013 SEP/ZRG1 CVRS-Q (02) – *ad hoc* reviewer
- 2014 SEP (member conflicts) *ad hoc* reviewer
- 2010–2015 Myocardial Ischemia and Metabolism (MIM) Study Section – *ad hoc* reviewer
- 2015–2018 Myocardial Ischemia and Metabolism (MIM) Study Section – **Regular Member**
- 2018–2020 Myocardial Ischemia and Metabolism (MIM) Study Section – **Chairperson**
- 2020 Aging Systems and Geriatrics (ASG) Study Section – *ad hoc* reviewer
- 2021 Centers of Biomedical Research Excellence (COBRE) Phase II [ZGM1 RCB-W (C2)] – *ad hoc* reviewer
- 2021 'F' Series Fellowship Review – *ad hoc* reviewer
- 2023 NIGMS Review of Institutional Development Award (IDeA) Networks for CTR (U54)
- 2023 NIGMS Review of K99 Mosaic Applications

American Diabetes Association:

- 2008–2014 Member, Research Grant Review Panel

American Heart Association:

- 2004–2006 Abstract grader for Scientific Sessions (Experimental Myocardial Infarction section)
- 2005–2014 Grant reviewer for AHA (multiple Cardiac Biology/Regulation study groups)

2010 Co-Chair, Cardiac Biology I Study Group (BCT1)
2011–2012 Grant reviewer for AHA Innovative Research Grants
2012 Member, Scientific Classification Task Force
2012–2016 Member, Membership/Communications Committee of BCVS Section
2012–present Abstract grader/programmer, AHA Scientific Sessions and/or BCVS summer conference
2014–2018 Member, Committee for Scientific Sessions Program; Invited Program Lead – Group 1
2014–2020 Member, Marcus Award Competition Committee
2019–present Lead (BCVS section), Committee for Scientific Sessions Programming

American Society for Pharmacology and Experimental Therapeutics:

2004–2006 Executive Committee Member and Counselor – Cardiovascular Section
2004–2006 Chair, Recruitment Committee – Cardiovascular Section
2006–2015 Member, Competition Committee – Cardiovascular Section
2008–2013 Chair/Co-Chair, Competition Committee – Cardiovascular Section
2008–2013 Executive Committee Member – Cardiovascular Section
2009–2018 Member, Communications Committee – Cardiovascular Section

International Society for Heart Research:

2015–2021 Councilor, North American Section

Veterans Affairs:

2017–2019 Robley Rex VA Medical Center, Louisville, KY
Member, Subcommittee on Research Safety
2019–2020 Robley Rex VA Medical Center, Louisville, KY
Chair, Subcommittee on Research Safety

Wellcome Trust:

2008 Senior Research Fellowship – *ad hoc* reviewer

Intramural Activities:

2005–2009; 2019 Judge for *Research!Louisville*
2007 (Feb) Judge for *Junior Science and Humanities Symposium* competition for high school students (finals)
2007–2009 Speaker for American Heart Association community events in Louisville
2008–2019 *Director*, Imaging and Physiology Core, Diabetes and Obesity Center, University of Louisville
2010 Mock NIH study section participant for *Research!Louisville*
2011 Member, University of Louisville Animal Research Advisory Committee
2011–2014 Member, *ad hoc* Ethics Panel Committee – DIO4139
2012–2017 Chair, Faculty Recruitment Committee (IMC)
2013 Member, Decanal Review Committee for RRC Director (W. W. King, DVM, PhD)
2015 Member, *ad hoc* Investigative Team – #A3586-01 (OLAW Case Z)
2017 Member, search committee for Technology Transfer officer
2018–2021 Member, School of Medicine Research Committee
2019–2021 Member, School of Medicine Strategic Planning Committee – Research
2019–2021 Member, University Grand Challenge Planning Committee – Research
2019–2022 Member, Task Force of Scientific Data Management & Sharing

Editorial Responsibilities

Associate/Consulting Editor:

2012–2018 *American Journal of Physiology—Heart and Circulatory Physiology*
2012–2016 *Frontiers in Striated Muscle Physiology* (resigned)

2017–2021 *Frontiers in Cardiovascular Metabolism* (resigned)
2021–present *American Journal of Physiology—Heart and Circulatory Physiology*

Editorial Board Membership:

2005–present *Circulation Research* (under three editors-in-chief)
2010–present *Journal of Molecular and Cellular Cardiology* (under three editors-in-chief)
2010–2021 *Basic Research in Cardiology*
2012–present *American Journal of Physiology—Heart and Circulatory* (under three editors-in-chief)
2012–2019 *Frontiers in Mitochondrial Research* (resigned)
2014–2019 *Molecular and Cellular Biochemistry*

Ad hoc Reviewer (selected, recent activity):

FASEB J, JACC, Circulation, PNAS, Journal of Clinical Investigation, JCI-Insight, EMBO Molecular Medicine, Circulation: Heart Failure, Circulation: Cardiovascular Genetics, Diabetes, Nature Communications

EDUCATIONAL ACTIVITIES

2009–2018 *Director, Cardiovascular Medicine Grand Rounds*

Formal Course Instruction:

2000: Department of Molecular and Cellular Physiology, LSU Health Sciences Center
Allied Health Physiology Course (~100 allied health students)
Lectures given: ‘Renal Physiology’ in two sessions

2001: Department of Molecular and Cellular Physiology, LSU Health Sciences Center
Allied Health Physiology Course (~100 allied health students)
Lectures given: ‘Renal Physiology’ in two sessions

2008: Department of Physiology and Biophysics, University of Louisville
“Hypothesis-Based Research” (PHZB 625)
Lectures given: ‘Mitochondria I’; ‘Mitochondria II’

2008: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lecture given: ‘Myocardial Ischemia’

2009: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lectures given: ‘Myocardial Ischemia I’; ‘Myocardial Ischemia II’

2009: Department of Physiology and Biophysics, University of Louisville
“Hypothesis-Based Research” (PHZB 625)
Lecture given: ‘Metabolic Signaling in Heart Disease’

2010: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lectures given: ‘Myocardial Ischemia I’; ‘Myocardial Ischemia II’

2011: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lectures given: ‘Myocardial Ischemia I’; ‘Myocardial Ischemia II’

- 2012: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lectures given: ‘Myocardial Ischemia I’; ‘Myocardial Ischemia II’; ‘Heart Failure I’;
‘Heart Failure II’
- 2013: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lectures given: ‘Myocardial Ischemia I’; ‘Myocardial Ischemia II’; ‘Heart Failure I’;
‘Heart Failure II’
- 2014: Distinction in Research Track (second year medical students)
Lecture given: “Presentation Skills”
- 2014: Department of Physiology and Biophysics, University of Louisville
“Advanced Cardiovascular Physiology” (PHZB 611)
Lectures given: ‘Heart Failure I’; ‘Heart Failure II’
- 2015: Distinction in Research Track (second year medical students)
Lecture given: “Presentation Skills”
- 2019: Mentorship Academy (graduate students from across campus)
Lecture given: “Communication Skills”
- 2021: Mentorship Academy (graduate students from across campus)
Lecture given: “Communication Skills”
- 2022: Mentorship Academy (graduate students from across campus)
Lecture given: “Mentorship Panel Discussion”

Mentor for Early Career Faculty:

- 2011–2015: Bradford G. Hill, PhD, Professor, University of Louisville, Diabetes and Obesity Center.
NIH (R01+) funded.
- 2012–2014: Kyung U. Hong, PhD, Assistant Professor, Department of Pharmacology and
Toxicology, University of Louisville.
- 2014–2017: Marcin Wysoczynski, PhD, Associate Professor, Diabetes and Obesity Center,
University of Louisville. NIH (R01+) funded.
- 2016–2018: Joseph B. Moore, IV, PhD, Associate Professor, Diabetes and Obesity Center,
University of Louisville. NIH (R01) funded.
- 2019–2021: Sujith Dassanayaka, PhD, Instructor, Envirome Institute, University of Louisville.
- 2020–2022: Helen Collins, PhD, Assistant Professor, Center for Cardiometabolic Science, University
of Louisville. NIH (R01) funded.
- 2021–2023: Brian Sansbury, PhD, Assistant Professor, Center for Cardiometabolic Science,
University of Louisville. NIH (R01) funded.

Mentor for Postdoctoral Fellows:

- 2007–2010: Heberty Facundo, PhD, University of Louisville; Sponsor of Dr. Facundo’s AHA
Postdoctoral Fellowship
Current position: Professor

Univ. Federal do Ceará—Campus Cariri
Brazil

2009–2015: Ayesha Zafir, PhD, University of Louisville; Sponsor of Dr. Zafir’s AHA Postdoctoral Fellowship

Current position: Instructor of Biological Sciences
Sullivan University
Louisville, KY

2011–2012: Ryan D. Readnow, PhD, University of Louisville

Current position: Medical Science Liaison
Eli Lilly
Louisville, KY

2011–2015: Senthilkumar Muthusamy, PhD, University of Louisville

Current position: Head, Research and Development
Cologenesis Healthcare Products, Pvt, Ltd
Salem, Tamil Nadu
India

2016–2019: Sujith Dassanayaka, PhD, University of Louisville

Current position: Instructor of Medicine
University of Louisville
Louisville, KY

Ph.D. Thesis Supervisor for:

2006–2009: Gladys A. Ngoh, PhD

Department of Physiology
University of Louisville

- AHA Predoctoral Fellow Awardee (Sponsor: Jones)
- *John Richard Binford Memorial Awardee for Excellence in Graduate Studies*
- *Graduate Dean’s Citation*

Subsequent position: Postdoctoral Fellow (Kenneth Walsh Laboratory), Boston
University Medical School, Division of Cardiovascular Medicine

Current position: Research Scientist, Janssen Pharmaceuticals (Johnson &
Johnson), Boston, MA

2007–2011: Lewis J. “Josh” Watson, PhD

Department of Physiology
University of Louisville

- AHA Predoctoral Fellow Awardee (Sponsor: Jones)
- Top Graduate Student Citation (School of Medicine)
- *Graduate Dean’s Citation*

Subsequent position: Postdoctoral Fellow, Laboratory of Howard Rockman, MD,
Division of Cardiology, Duke University School of Medicine

Current position: Associate Professor, Georgetown University, Washington, DC

2008–2012: Robert E. “Eli” Brainard, PhD

Department of Physiology
University of Louisville

- AHA Predoctoral Fellow Awardee (Sponsor: Jones)
- *Graduate Dean’s Citation*

Subsequent position: Postdoctoral Fellow, Laboratory of Daniel Kelly, MD
Burnham Institute for Medical Research, Orlando, FL

Current position: Assistant Professor, University of Louisville, Louisville, KY

- 2012–2016: Sujith Dassanayaka, PhD
Department of Physiology
University of Louisville
- AHA Predoctoral Fellow Awardee (Sponsor: Jones)
- *John Richard Binford Memorial Awardee*
- *Graduate Dean's Citation*
Current position: Instructor, Envirome Institute, University of Louisville, Louisville, KY
- 2017–2021: Timothy N. Audam, PhD
Department of Biochemistry and Molecular Genetics
University of Louisville
- AHA Predoctoral Fellow Awardee (Sponsor: Jones)
- *Graduate Dean's Citation*
Current position: Research Scientist, Broad Institute, Cambridge, MA
- 2020–present: Danielle Little, MS
Department of Biochemistry and Molecular Genetics
University of Louisville
- NIH F31 Awardee (Sponsor: Jones)
- 2022–present: Caitlin Howard, BS
Department of Biochemistry and Molecular Genetics
University of Louisville

Master's Degree Advisor for:

- 2007–2008: Ashley L. Robertson, MS, Department of Physiology, University of Louisville
- 2015–2016: James Bradley, MS, Department of Biochemistry and Molecular Genetics, University of Louisville
- 2021–2022: Deepak Sharma, MS, Department of Physiology, University of Louisville

Ph.D. Thesis Committee Member for:

- 2007–2009: Rachel J. Keith, PhD, University of Louisville, Department of Physiology
(advisor: Aruni Bhatnagar, PhD)
- 2007–2011: Qianwen 'Sharon' Wang, MS, PhD, University of Louisville, Department of Physiology
(advisor: Paul Epstein, PhD)
- 2008–2010: Robert K. Lewis, MD, PhD, University of Louisville, Department of Physiology
(advisor: Sumanth D. Prabhu, MD)
- 2010–2011: Timothy D. Cummins, PhD, University of Louisville, Department of Biochemistry
(advisor: David Powell, PhD)
- 2010–2012: Joshua Salabei, MS, PhD, University of Louisville, Department of Biochemistry
(advisors: Aruni Bhatnagar, PhD, and Bradford G. Hill, PhD)
- 2010–2014: Brian Sansbury, MS, University of Louisville, Department of Physiology and Biophysics
(advisors: Bradford Hill, PhD, and Aruni Bhatnagar, PhD)

- 2011–2012: Alan Brooks, PhD, (MD/PhD student) University of Louisville, Department of Biochemistry (advisor: Aruni Bhatnagar, PhD)
- 2011–2012: Mehak Goel, MS, University of Louisville, Department of Physiology (advisor: Sumanth D. Prabhu, M.D.). Transferred with advisor to UAB to complete her PhD.
- 2012–2013: Rebekka V. Jensen, PhD, Århus University, Århus, Denmark. Role: External 'Opponent' (advisor: Hans Erik Bøtker, MD)
- 2013–2014: Yubing Wan, PhD, University of Texas-Pan American, Department of Bioinformatics and Biostatistics (advisors: Maiying Kong, PhD, and Susmita Datta, PhD)
- 2013–2015: Bathri N. Vajravelu, PhD, University of Louisville, Department of Pharmacology & Toxicology (advisors: Kyung Hong, PhD, and Aruni Bhatnagar, PhD)
- 2013–2015: Tareq Mohammed Mugahed Al-Maqtari, MS, University of Louisville, Department of Pharmacology & Toxicology (advisors: Kyung Hong, PhD, and Aruni Bhatnagar, PhD)
- 2017–2021: Marc Dwenger, BS, University of Louisville, Department of Pharmacology & Toxicology (advisor: Matthew A. Nystoriak, PhD)
- 2019–2021: Sophia Marie Sears, BS, University of Louisville, Department of Pharmacology & Toxicology (advisor: Leah Siskind, PhD)
- 2019–2022: Sean M. Raph, BS, University of Louisville, Department of Pharmacology & Toxicology (advisor: Matthew A. Nystoriak, PhD)
- 2019–2022: Kyle Fulghum, BS, University of Louisville, Department of Physiology (advisor: Bradford G. Hill, PhD)
- 2021–2023: Andrew J. Orwick, BS, University of Louisville, Department of Pharmacology & Toxicology (advisor: Leah Siskind, PhD)
- 2020–present: Annalara Fischer, BS, University of Louisville, Department of Biochemistry (advisor: Joseph B. Moore, IV, PhD)
- 2022–present: Daniel Nguyen, BS, University of Louisville, Department of Physiology (advisor: Bradford Hill, PhD)
- 2023–present: Collin Wells, BS, University of Louisville, Department of Biochemistry and Molecular Genetics (advisor: Bradford Hill, PhD)
- 2023–present: Britney Reynolds, BS, University of Louisville, Department of Physiology (advisor: Alex Carll, PhD)

Master's Degree Committee Member for:

- 2009: Allison Keskey, MS, University of Louisville, Department of Physiology (advisor: Sumanth D. Prabhu, MD)
- 2023: Dana Hammouri, MS, University of Louisville, Department of Pharmacology & Toxicology (advisor: Tamer Mohamed, PhD)

Graduate Student Rotation Preceptor for (does not include students who joined the laboratory):

- 2011: David Tran, MS, Department of Physiology, University of Louisville

2013: Andrew Gibb, BS, Department of Physiology, University of Louisville
2016: Weiyang Ying, MD, Department of Pharmacology and Toxicology, University of Louisville
2016: Rubens Petit Homme, BS, Department of Physiology, University of Louisville
2018: Micaela Reeves, BS, Department of Pharmacology and Toxicology, University of Louisville
2018: Kyle Fulghum, BS, Department of Physiology, University of Louisville
2019: Makayla Brady, BS, Department of Biochemistry and Molecular Genetics, University of Louisville
2019: Kennedy Walls, BS, Department of Pharmacology and Toxicology, University of Louisville
2020: Raeden Gray, BS, Department of Biochemistry and Molecular Genetics, University of Louisville
2022: Dana Hammouri, BPharm, Department of Pharmacology and Toxicology, University of Louisville

M.D. Student Research Internship Mentor for:

2008 (Jun–Aug): Benjamin Brown, BS, MSY-1, University of Louisville School of Medicine
2009 (Jun–Aug): Kewakebt M. Lemma, BS, MSY-1, University of Louisville School of Medicine
2010 (Jun–Aug): Philip M. Stoller, BS, MSY-1, University of Louisville School of Medicine
2016 (Jun–Jul): Maryam Khan, BS, MSY-1, University of Louisville School of Medicine

Undergraduate Student Research Mentor for:

2008: Samantha Shirk, Indiana University
2009: Catherine Sherman, University of Southern California
2009–2010: Felicia Hogan, R25-supported undergraduate, University of Louisville (Ms. Hogan was a *Fulbright Scholar*)
2010: Jesse Wilson, University of Louisville
2010: Aaron Tyagi, University of Louisville
2011: Alejandro Alvarez, R25-supported undergraduate, University of Louisville
2014: Shanique Ries, R25-supported undergraduate, Western Illinois University
2016–2017: Mitali Chitre, University of Louisville
2018–2019: Lauren Higgins, BS, Bioengineering Co-op Student, University of Louisville
2018–2020: Yi Wei “Kevin” Zheng, BS, Bioengineering Co-op Student, University of Louisville
2019–2021: Caitlin Howard, BS, Bioengineering Co-op Student, University of Louisville
2020–2022: Lauren Garrett, Bioengineering Co-op Student, University of Louisville
2021–2022: Exile Lukudu, AHA Undergraduate Internship, University of Louisville
2021–2023: Juliette Smith, Bioengineering Co-op Student, University of Louisville
2022–2023: Sarah Belcher, R25-supported undergraduate, University of Louisville
2022–pres: Casey Colley, Bioengineering Co-op Student, University of Louisville
2022–pres: Emma Pendergraft, Bioengineering Co-op Student, University of Louisville
2023–pres: Samantha Becker, Bioengineering Co-op Student, University of Louisville

High School Student Research Internship Mentor for:

2009–2010: Jamshed Kaikaus, DuPont Manual High School, Louisville, KY
Mr. Kaikaus won first place in the regional science fair.
2016: Lekka Challapa, Kentucky Country Day, Louisville, KY

GRANTS AND CONTRACTS

Active Extramural Grant Support

As PI:

- | | | |
|--|-----------------------|---------------------------|
| 1. R01 HL163272 (PI: Jones) | 04/01/2022–03/31/2026 | 4.0 cal mo. |
| NIH/NHLBI | | \$2,167,407 (total costs) |
| <i>“Extracellular Matrix Dynamics During Remodeling”</i> | | |

The goal is to understand where hyaluronan is produced and how changes in its production impact ventricular remodeling.

Role: Principal Investigator

2. AHA Transformation Project Award #970338 (PI: Jones) 07/01/2022–06/30/2025 1.2 cal mo.
American Heart Association \$300,000 (total costs)
“Hyaluronan Metabolism in the Failing Heart”
This project will address how metabolism of hyaluronan is regulated in the heart.
Role: Principal Investigator

3. IAUST00215726 (PI: Jones) 01/01/2022–12/31/2024 0.3 cal mo.
American Heart Association \$165,000 (total costs)
“Louisville Undergraduate training Program (LV-UP)”
This AHA-funded undergraduate program provides meaningful research experiences for undergraduates interested in cardiovascular science.
Role: Principal Investigator/Program Director

4. R01 HL147844 (Hill/Jones; MPI; NCE) 08/01/2019–07/31/2024 1.2 cal mo.
NIH/NHLBI ~\$2,800,000 (total costs)
“Biosynthetic Pathways in Cardiac Remodeling”
This project will address the relationship between glycolytic catabolic and anabolic pathways in diseased and healthy hearts.
Role: Principal Investigator (MPI with Hill)

5. P30 GM127607 (PI: Jones; NCE) 07/01/2018–06/30/2024 1.2 cal mo.
NIH/NIGMS ~\$5,775,000 (total costs)
“Center for Excellence in Diabetes and Obesity Research”
This “Phase 3” award supports the sustainability of the core services of the Center for Cardiometabolic Science.
Role: Overall PI

As Sponsor/Mentor:

6. F32 HL149140 (Sponsors: Jones and Hill) 01/01/2021–12/31/2023 0.0 cal mo.
NIH/NHLBI
“Deciphering the Relationship Between Cardiomyocyte Metabolic Configuration and Cell Cycle Re-entry”
This is an NIH individual postdoctoral fellowship for Dr. Riham Abouleisa (postdoctoral fellow).
Role: Co-Sponsor (Co-Mentor)

7. F31 HL162518 (Sponsor: Jones) 02/01/2022–01/31/2025 0.0 cal mo.
NIH/NHLBI
“Dynamic Role of Hyaluronan in Ventricular Remodeling”
This is an NIH individual predoctoral fellowship for Danielle Little (PhD student).
Role: Sponsor (Mentor)

8. 23PRE1018548 (Sponsors: Hill and Jones) 01/01/2023–12/31/2024 0.0 cal mo.
American Heart Association
“Fibroblast TAK1 Signaling in Cardiac Fibrosis”
This is an AHA individual predoctoral fellowship for Daniel Nguyen (MD/PhD student).
Role: Co-Sponsor (Co-Mentor)

As Co-Investigator:

9. R21 ES033334 (PI: Zelko) 07/01/2022–06/30/2024 0.6 cal mo.
NIH/NIEHS salary only
“Benzene Exposure and Heart Failure”

This work will uncover the extent to which benzene exposures exacerbate heart failure.

Role: Co-Investigator

- | | | |
|---|-----------------------|-----------------------------|
| 10. P42 ES023716 (PI: Srivastava)
NIH/NIEHS
<i>"Environmental Exposure and Cardiometabolic Disease"</i>
This Center grant will support research on the cardiometabolic effects of volatile organic chemicals (VOCs) that are of high relevance to the Superfund Program.
Role: <u>Co-Investigator</u> | 09/01/2022–06/30/2027 | 0.48 cal mo.
salary only |
| 11. R01 HL163003 (PI: Collins)
NIH/NHLBI
<i>"Metabolic Mechanisms of Pregnancy-Induced Hypertrophy"</i>
This project will elucidate the metabolic changes required to support cardiac adaptation in the maternal heart.
Role: <u>Co-Investigator</u> | 12/01/2022–11/30/2027 | 0.6 cal mo.
salary only |

Pending Extramural Grant Support

12. Co-Investigator on multiple NIH applications

COMPLETED Grant Support

Extramural

As Principal Investigator:

- | | | |
|--|---------------------|-------------|
| 1. American Heart Association National Center – SDG 053270N
<i>"Metabolic Post-Translational Modification in the Mechanism of Myocardial Injury and Protection"</i>
07/01/2005–06/30/2009
Role: <u>Principal Investigator</u> | Total direct costs: | \$235,864 |
| 2. Pfizer – Atorvastatin Research Award
<i>"Mechanisms of Cardioprotection During Chronic Atorvastatin Treatment"</i>
2006
Role: <u>Principal Investigator</u> | Total direct costs: | \$45,500 |
| 3. National Institutes of Health – R01 HL083320 (Jones)
<i>"Metabolic Mechanisms of Cardiac Injury and Protection"</i>
07/15/2006–06/30/2011
Role: <u>Principal Investigator</u> | Total direct costs: | \$1,125,000 |
| 4. Trophos (biopharmaceutical company in France; acquired by Hoffmann-La Roche in 2015)
<i>"Cardioprotective Mechanisms of TRO03430"</i>
07/01/2008–06/30/2009
Role: <u>Principal Investigator</u> | Total direct costs: | \$25,000 |
| 5. Kentucky Science & Engineering Foundation – RDE 07-0611
<i>"O-GlcNAc Signaling in the Heart"</i>
07/01/2008–06/30/2010
Role: <u>Principal Investigator</u> | Total direct costs: | \$90,954 |
| 6. National Institutes of Health – R01 HL094419 (Jones)
<i>"O-GlcNAc Signaling in Heart Failure"</i> | | |

08/01/2009–06/30/2013 Role: <u>Principal Investigator</u>	Total direct costs:	\$1,000,000
7. National Institutes of Health – R01 HL083320-S1 (Jones) <i>“Metabolic Mechanisms of Cardiac Injury and Protection”</i> 09/01/2009–06/30/2012 Role: <u>Principal Investigator</u>	Total direct costs:	\$166,951
8. National Institutes of Health – R01 HL131647 (Jones) <i>“Regulation of Metabolic Genes in the Heart”</i> 06/01/2016–05/31/2021 Role: <u>Principal Investigator</u>	Total direct costs:	\$1,480,000
9. National Institutes of Health – S10 OD025178 (Jones) <i>“Imaging and Physiology Core: High Frequency, High Resolution Ultrasound System”</i> 06/01/2019–05/31/2020 Role: <u>Principal Investigator</u>	Total direct costs:	\$363,800
10. P30 GM127607-04S1 (PI: Jones) NIH/NIGMS <i>Supplement for Sable System</i> This supplement supports the purchase of an 8-channel metabolic cage system. 07/01/2021–06/30/2022 Role: <u>PI</u>	Total direct costs:	\$249,999
11. P01 HL078825 (Project 3 PI: Jones) NIH/NHLBI <i>Project 3: “Cell Therapy and Remodeling”</i> These experiments will elucidate mechanistic effects of cell therapy on ventricular remodeling. 09/01/2011–08/31/2022 Role: <u>PI of Project 3</u>	Total costs:	~\$3,200,000
12. P30 GM127607-05S1 (PI: Jones) NIH/NIGMS <i>Implementing Biomechanics Instrumentation in the Center</i> This supplement supports the purchase of an atomic force microscopy system for interrogation of stiffness and other viscoelastic properties of tissues. 08/03/2022–06/30/2023 Role: <u>Principal Investigator</u>	Total direct costs:	\$249,000

As Sponsor/Mentor:

13. American Heart Association – (0715493B) Predoctoral Fellowship for Gladys A. Ngoh, PhD 07/01/2007–06/30/2009 Role: <u>Sponsor (Mentor)</u>	Total direct costs:	\$42,000
14. American Heart Association – (0815502D) Predoctoral Fellowship for Lewis J. Watson, PhD 07/01/2008–06/30/2010 Role: <u>Sponsor (Mentor)</u>	Total direct costs:	\$42,000
15. American Heart Association – (0825643D) Postdoctoral Fellowship for Heberty Facundo, PhD 07/01/2008–06/30/2010	Total direct costs:	\$88,000

Role: Sponsor (Mentor)

16. American Heart Association – (09PRE2390017)
Predoctoral Fellowship for Robert E. Brainard, PhD
07/01/2009–06/30/2011
Role: Sponsor (Mentor)
Total direct costs: \$46,000
17. American Heart Association
Postdoctoral Fellowship for Ayesha Zafir, PhD
01/01/2014–12/31/2015
Role: Sponsor (Mentor)
Total direct costs: \$88,000
18. American Heart Association
Predoctoral Fellowship for Sujith Dassanayaka, PhD
07/01/2014–06/30/2016
Role: Sponsor (Mentor)
Total direct costs: \$46,000
19. 17MM33660235 (PI: Jones)
American Heart Association
AHA Mentor/Mentee Award
07/01/2017–06/30/2020
Role: PI (Mentor)
Total direct costs: \$60,000
20. 19PRE34380003 (Sponsor: Jones)
American Heart Association
Predoctoral fellowship for Timothy Audam
01/01/2018–12/31/2020
Role: Sponsor (Mentor)
Total direct costs: \$53,000
21. F31 HL154663 (Sponsors: Hill and Jones)
NIH/NHLBI
This was an NIH individual predoctoral fellowship for Kyle Fulghum.
08/10/2020–01/31/2023
Role: Co-Sponsor (Co-Mentor)
Total direct costs: \$104,130

Presentations

Invited Seminars/Symposia/Grand Rounds (excludes abstract oral presentations)

1. **03/19/2001:** *Spring Seminar Series.* Department of Physiology, Louisiana State University Health Sciences Center, Shreveport, LA.
2. **05/18/2001:** *Graduate Student Seminar Series.* School of Graduate Studies, Louisiana State University Health Sciences Center, Shreveport, LA.
3. **06/11/2001:** Institute of Molecular Medicine, Department of Medicine, University of California at San Diego, La Jolla, CA.
4. **07/11/2001:** *Merck Frosst Symposium: Atherosclerosis and Diabetes.* 17th World Congress of the International Society for Heart Research, Winnipeg, Canada.
5. **06/25/2001:** Department of Biochemistry, Duke University School of Medicine, Durham, NC.
6. **09/10/2001:** Institute of Molecular Cardiobiology, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD.
7. **10/13/2001:** *Gastrointestinal Response to Injury - 2001.* Montebello, Canada.
8. **11/15/2001:** Division of Cardiology, Department of Medicine, Veterans Affairs Medical Center/University of California at San Diego, La Jolla, CA.

9. **02/12/2002**: Whitaker Cardiovascular Institute, Department of Medicine, Boston University Medical Center, Boston, MA.
10. **05/05/2004**: Institute of Molecular Cardiology, Division of Cardiology, Department of Medicine, University of Louisville School of Medicine, Louisville, KY.
11. **06/07/2004**: Department of Physiology, Tulane University School of Medicine, New Orleans, LA.
12. **09/22/2004**: Cardiology Grand Rounds, Department of Medicine, University of Louisville School of Medicine, Louisville, KY.
13. **09/28/2004**: Research Seminar Series, Department of Physiology and Biophysics, University of Louisville School of Medicine, Louisville, KY.
14. **04/05/2005**: "Endothelial Nitric Oxide and Cardiovascular Disease". XXXV International Congress of Physiological Sciences 2005. San Diego, CA.
15. **12/14/2005**: Cardiology Grand Rounds, Department of Medicine, University of Louisville School of Medicine, Louisville, KY.
16. **12/16/2005**: Hypertension and Vascular Biology Group, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL.
17. **10/18/2006**: "Sugarcoating the Heart: Unique Metabolic Insights into Postischemic Myocardial Injury". Cardiology Grand Rounds, Department of Medicine, University of Louisville School of Medicine, Louisville, KY.
18. **01/23/2007**: "Sugarcoating the Heart: Unique Metabolic Insights into Postischemic Myocardial Injury". Departmental Seminar Series, Department of Physiology and Biophysics, University of Louisville School of Medicine, Louisville, KY.
19. **04/28/2007**: "O-GlcNAc and Protection of Ischemic Myocardium". Experimental Biology Meeting. Washington, DC.
20. **09/11/2007**: "Noncanonical Glycosylation in the Heart". Division of Cardiovascular Medicine, Albert Einstein College of Medicine. Bronx, NY.
21. **11/06/2007**: "O-GlcNAc in Cardiovascular Biology". American Heart Association Scientific Sessions. Orlando, FL.
22. **03/26/2008**: "Noncanonical Signaling via Glucose in the Heart". Cardiology Grand Rounds, Department of Medicine, University of Louisville School of Medicine, Louisville, KY.
23. **09/05/2008**: "Glucose-Derived Metabolic Signaling in the Cardiovascular System". *Department of Medicine, Division of Pulmonology, Critical Care, and Sleep Disorders Medicine Research Series*. University of Louisville. Louisville, KY.
24. **09/08/2008**: "Metabolic Signaling in Diabetes and Heart Disease: Role of O-GlcNAc". *Department of Biochemistry and Molecular Biology Seminar Series*. University of Louisville. Louisville, KY.
25. **09/17/2008**: "The Hexosamine Biosynthetic Pathway and Cardiovascular Disease". *Department of Physiology Seminar Series*. LSU Health Sciences Center, Shreveport, LA.
26. **03/18/2009**: "Metabolic Signaling in the Cardiovascular System". *Cardiology Ground Rounds*. Department of Medicine. University of Louisville School of Medicine, Louisville, KY.
27. **09/17/2009**: "O-GlcNAc in the Pathobiology of Cardiovascular Disease". *Free Radical Biology Center*. University of Alabama—Birmingham. Birmingham, AL.
28. **03/10/2010**: "Metabolic Signaling in Heart Disease". *Division of Cardiovascular Medicine Grand Rounds*. University of Louisville School of Medicine. Louisville, KY.
29. **03/17/2010**: "O-GlcNAc Signaling in Cardiac Pathophysiology". *Department of Pharmacology and Toxicology Seminar Series*. Medical College of Wisconsin. Milwaukee, WI.
30. **04/27/2010**: "Surviving on Sugar: Cardioprotection with a Unique Metabolic Signal". In session, entitled *Novel Molecular Targets for Modulating Cardiac Cell Death and Survival*. Experimental Biology. Anaheim, CA.
31. **07/18/2010**: "O-GlcNAc Signaling in Cardiovascular Disease". *Basic Cardiovascular Sciences Council Satellite Symposium on Genes, Proteins, and Cardiovascular Medicine*. Palm Springs, CA.
32. **11/14/2010**: "Glycosylation and Cardiovascular Signaling". In session on *Novel Post-Translational Modifications and their Cardiovascular Significance*. American Heart Association Scientific Sessions. Chicago, IL.
33. **12/06/2010**: "Metabolic Signaling in the Cardiovascular System: The Role of O-GlcNAc". *Cardiovascular Medicine Research Seminar*. Emory University. Atlanta, GA.
34. **01/26/2011**: "Metabolic Signaling in the Heart". *Cardiovascular Medicine Grand Rounds*. University of Louisville. Louisville, KY.

35. **05/17/2011**: "Protein O-GlcNAcylation: How a Sugar Regulates the Heart". *Integrative Program in Comparative Medicine Seminar Series*. Yale University. New Haven, CT.
36. **08/18/2011**: "Protein O-GlcNAcylation in the Cardiovascular System". *Department of Pharmacology and Toxicology Seminar Series*. University of Louisville. Louisville, KY.
37. **08/31/2011**: "Protein O-GlcNAcylation: How a Sugar Regulates the Heart". *COOL (COmmunicating with Outstanding Leaders) Lecture*. Inje University. Busan, Korea.
38. **09/01/2011**: "O-GlcNAc Signaling in the Cardiovascular System." *The Satellite Symposium of Korean Society of Lipidology and Atherosclerosis Annual Scientific Conference 2011, in conjunction with 5th MRCITR (Myocardial Center for Ischemic Tissue Regeneration) International Symposium*. Busan National University. Busan, Korea.
39. **09/03/2011**: "O-GlcNAc Signaling in the Heart." *The Korean Society of Lipidology and Atherosclerosis Annual Scientific Conference 2011*. Grand Hilton Seoul. Seoul, Korea.
40. **11/14/2011**: "Role of O-GlcNAc in Regulation of Cardiac Hypertrophy". In Session: *Posttranslational Regulation in Cardiac Physiology and Disease*. The American Heart Association Scientific Sessions. Orlando, FL.
41. **09/05/2012**: "Protein O-GlcNAcylation: How a Sugar Can Regulate the Heart". Institute of Cardiovascular Sciences. University of Manitoba. Winnipeg, MB, Canada.
42. **11/02/2012**: "O-GlcNAcylation, Cell Survival, and the Heart". In *New Horizons in Cardioprotection Symposium*. AHA Satellite Symposium. UCLA. Los Angeles, CA.
43. **01/24/2013**: "Metabolism and Cardiovascular Disease". *Comprehensive Cardiovascular Center Seminar*. University of Alabama – Birmingham. Birmingham, AL.
44. **05/26/2013**: "Hexosamine Biosynthetic Pathway and the Heart". 7th Oriental Cardiology Conference. Shanghai, China.
45. **08/17/2013**: "O-GlcNAc in the Cardiovascular System". International Academy of Cardiovascular Sciences. Louisville, KY.
46. **10/25/2013**: "O-GlcNAc in the Heart". Department of Physiology Seminar Series. University of Buffalo. Buffalo, NY.
47. **11/17/2013**: "O-GlcNAc Modification and the Relationship Between Metabolism and Heart Failure". In session: *Emerging Post-Translational Modifications in Heart Failure*. American Heart Association Scientific Sessions. Dallas, TX.
48. **06/05/2014**: "Metabolism in Heart Failure". Northwestern University. Chicago, IL.
49. **09/06/2014**: "Metabolic Signaling in Heart Failure". International Academy of Cardiovascular Sciences – North American Section. Winnipeg, Canada.
50. **10/11/2014**: "Protein O-GlcNAcylation in Cardiovascular Disease". International Academy of Cardiovascular Sciences – European Section. Balatonyörök, Hungary.
51. **11/05/2014**: "Unique Aspects of Metabolic Signaling in Heart Disease". Vascular Biology Center Seminar Series, Georgia Regents University. Augusta, GA.
52. **04/21/2015**: "Metabolic Signaling in the Heart". Cardiovascular Research Center. Temple University. Philadelphia, PA.
53. **07/14/2015**: "Protein O-GlcNAcylation in the Heart". AHA BCVS Conference. New Orleans, LA.
54. **09/02/2015**: "Metabolic Signaling in the Heart". Diabetes and Obesity Center Seminar Series. University of Louisville. Louisville, KY.
55. **11/09/2015**: "O-GlcNAc Signaling Mechanisms to Protect the Heart". In session: *Cardiac Cell Death: Prevention and Recovery*. AHA Scientific Sessions. Orlando, FL.
56. **11/17/2015**: "Unique Metabolic Signaling in the Cardiovascular System". Northeast Ohio University Medical University.
57. **03/17/2016**: "Unique Metabolic Signaling in the Cardiovascular System". University of South Dakota, Vermillion, SD.
58. **04/28/2016**: "Metabolic Signaling in the Heart". University of Rochester, Rochester, NY.
59. **07/21/2016**: "Metabolic Signaling in the Heart". AHA BCVS Conference. Phoenix, AZ.
60. **08/29/2016**: "Metabolism, Remodeling, and Heart Failure". LSUHSC Cardiovascular Center of Excellence Seminar Series, New Orleans, LA.
61. **11/09/2016**: "Unique Metabolic Signaling in the Heart". Lillehei Heart Institute Lecture. University of Minnesota, Minneapolis, MN.
62. **12/06/2016**: "Unique Aspects of Metabolism in the Heart". Department of Biochemistry Seminar Series, University of Louisville, Louisville, KY.

63. **01/11/2017**: “Unique Aspects of Metabolism in the Heart”. Division of Cardiology. Johns Hopkins University, Baltimore, MD.
64. **01/24/2017**: “Unique Aspects of Metabolism in the Heart”. Division of Cardiology. UT Southwestern Medical Center, Dallas, TX.
65. **03/08/2017**: “Unique Aspects of Metabolism in the Heart”. Division of Cardiology. Kansas University Medical Center, Kansas City, KS.
66. **05/31/2017**: “O-GlcNAcylation in Heart Failure”. International Society for Heart Research—North American Section. New Orleans, LA.
67. **11/08/2017**: “Glucose: Not Just Another Fuel for the Heart”. Medical College of Wisconsin. Milwaukee, WI.
68. **12/19/2017**: “Glucose: Not Just Another Fuel for the Heart”. Biomedical Engineering-Pathology-Surgery Joint Seminar Series. University of Alabama—Birmingham. Birmingham, AL.
69. **02/28/2018**: “Glucose: Not Just Another Fuel for the Heart”. Vascular Medicine Institute Seminar Series. University of Pittsburgh. Pittsburgh, PA.
70. **03/15/2018**: “Non-catabolic Fates of Glucose in the Heart”. Department of Cellular and Integrative Physiology. University of Nebraska Medical Center. Omaha, NE.
71. **03/29/2018**: “Glucose: Not Just Another Fuel for the Heart”. Pauley Cardiovascular Center Seminar Series. Medical College of Virginia. Richmond, VA.
72. **05/17/2018**: “Glucose: Not Just Another Fuel for the Heart”. Hellenic Cardiovascular Conference. Athens, Greece.
73. **07/17/2018**: “Outstanding Investigator Award Lecture”. International Society for Heart Research—European Section. Amsterdam, The Netherlands.
74. **12/03/2018**: “An Untraditional Metabolic Perspective on Ventricular Remodeling”. Cardiovascular Center Seminar Series. University of Cincinnati. Cincinnati, OH.
75. **03/11/2019**: “An Untraditional Metabolic Perspective on Ventricular Remodeling”. University of California—Los Angeles. Los Angeles, CA.
76. **04/26/2019**: “Metabolic Pathways Dictating Extracellular Matrix Biology”. Wuhan International Conference on Liver and Cardiovascular Science. Wuhan, China.
77. **07/28/2019**: “Metabolic Signaling in the Heart”. Academy of Cardiovascular Research Excellence – part of the Asian Cardiovascular Sciences pre-BCVS conference. Boston, MA.
78. **07/29/2019**: “Linking Metabolism to the Extracellular Matrix”. AHA Basic Cardiovascular Sciences Conference. Boston, MA.
79. **09/24/2019**: “Linking Metabolism to the Extracellular Matrix”. Distinguished Seminar Speaker Series. University of Washington. Seattle, WA.
80. **11/12/2019**: “Metabolism and the Extracellular Matrix: A Convenient Relationship”. Frontiers Seminar Series. Stanford Cardiovascular Institute. Stanford University. Palo Alto, CA.
81. **01/27/2020**: “The Extracellular Matrix at the Crossroads of Metabolism and Remodeling”. Cardiovascular Biology Seminar. Division of Cardiology. Emory University. Atlanta, GA.
82. **02/28/2020**: “The Extracellular Matrix at the Crossroads of Metabolism and Remodeling”. Cardiovascular Research Seminar Series. Ohio State University. Columbus, OH.
83. **03/02/2020**: “The Extracellular Matrix at the Crossroads of Metabolism and Remodeling”. Department of Physiology Seminar Series. LSU Health – Shreveport. Shreveport, LA.
84. **11/17/2020**: “Trending Topics in Basic Science”. Closing session of American Heart Association Scientific Sessions. Dallas, TX. (Virtual)
85. **04/06/2021**: “Metabolic Regulation of Tissue Structure and Function: The Heart of the Matter”. Department of Physiology. Drexel University. Philadelphia, PA.
86. **08/12/2021**: “Cardiac Metabolism at the Crossroads of Health and Disease”. Department of Pharmacology and Toxicology. University of Louisville. Louisville, KY.
87. **09/16/2021**: “Metabolic Regulation of Cardiac Structure and Function”. International Society for Heart Research—North American Section. Denver, CO.
88. **11/12/2021**: “Trending Topics in Basic Science”. Closing session of American Heart Association Scientific Sessions. Boston, MA.
89. **04/30/2022**: “Metabolic Coordination of Ventricular Remodeling”. Second Olympiad of Cardiovascular Science. Heraklion, Crete, Greece.
90. **09/07/2022**: “Metabolic Regulation of the Extracellular Matrix”. International Society for Heart Research—North American Section. Winnipeg, Canada. (flight canceled; could not attend)

91. **11/07/2022:** “Closing Session of AHA Scientific Sessions”. American Heart Association Scientific Sessions. Chicago, IL.
92. **02/07/2023:** “Metabolic Regulation of the Extracellular Matrix”. Departmental Seminar Series. Department of Pharmacology, University of Cincinnati, Cincinnati, OH.
93. **02/16/2023:** “Metabolic Regulation of the Extracellular Matrix”. Diabetes Center Seminar Series. Diabetes Center, University of Iowa, Iowa City, IA. BEING RESCHEDULED

Chair/Moderator at National/International Conferences

1. **11/11/2003:** Moderator: “Inflammation and Other Therapeutic Targets in Myocardial Hypertrophy and Failure”. American Heart Association Scientific Sessions. Orlando, FL.
2. **04/19/2004:** Co-chair: “Division for Cardiovascular Pharmacology Graduate Student and Postdoctoral Scientist Best Paper Competition”. Experimental Biology Meeting. Washington, DC.
3. **11/08/2004:** Moderator: “Mechanisms of Cardioprotection”. American Heart Association Scientific Sessions. New Orleans, LA.
4. **04/08/2005:** Chair/Organizer: “Novel Insights into Myocardial Preconditioning: From the Clinic to the Proteome”. Experimental Biology Meeting. San Diego, CA.
5. **11/14/2005:** Moderator: “Nitric Oxide and cGMP-Dependent Cardioprotection”. American Heart Association Scientific Sessions. Dallas, TX.
6. **04/30/2007:** Chair/Organizer: “Breakthroughs in Protection of the Ischemic Heart”. Experimental Biology Meeting. Washington, DC.
7. **11/04/2007:** Moderator: “Myocardial Structure and Pathology: New Developments”. American Heart Association Scientific Sessions. Orlando, FL.
8. **11/05/2007:** Moderator: “Novel Insights into Myocardial Ischemia and Repair II”. American Heart Association Scientific Sessions. Orlando, FL.
9. **11/06/2007:** Moderator: “Proteomics and Post-Translational Modifications in the Heart”. American Heart Association Scientific Sessions. Orlando, FL.
10. **04/21/2009:** Chair/Organizer: “The Donald Reis Memorial Symposium: Metabolic Defects in Diabetes, Obesity, and Heart Failure”. Experimental Biology 2009. New Orleans, LA.
11. **08/17/2013:** Chair/Organizing Committee: “Autophagy, Mitochondria, and Cell Death”. International Academy of Cardiovascular Sciences. Louisville, KY.
12. **11/19/2013:** Chair: “Novel Mechanisms of Cardioprotection and Stem Cell Mediated Repair”. American Heart Association Scientific Sessions. Dallas, TX.
13. **04/29/2014:** Co-chair: “Cardiovascular Pharmacology Division Trainee Showcase”. Experimental Biology 2014. San Diego, CA.
14. **11/09/2015:** Moderator: “Melvin Marcus New Investigator Competition”. American Heart Association Scientific Sessions. Orlando, FL.
15. **11/09/2015:** Poster Professor: “Ventricular Function/Mechanics”. American Heart Association Scientific Sessions. Orlando, FL.
16. **11/13/2016:** Moderator: “Melvin Marcus New Investigator Competition”. American Heart Association Scientific Sessions. New Orleans, LA.
17. **11/14/2016:** Moderator: “Apoptosis, Necrosis, and Autophagy: 3 Shades of Cell Death”. American Heart Association Scientific Sessions. New Orleans, LA.
18. **11/12/2017:** Moderator: “Post-Translational Regulation of the Cardiac Proteome”. American Heart Association Scientific Sessions. Anaheim, CA.
19. **11/12/2018:** Moderator: “Extracellular Matrix: Fibroblasts and More”. American Heart Association Scientific Sessions. Chicago, IL.
20. **11/07/2019:** Chair: “Environmental Cardiology”. Southeast IDeA (NIH) Conference. Louisville, KY.
21. **11/18/2019:** Moderator: “Trending Topics in Basic Science”. American Heart Association Scientific Sessions. Philadelphia, PA.
22. **07/26/2022:** Moderator: “Hot Topics in Fibroblast Biology”. American Heart Association Basic Cardiovascular Sciences Council. Chicago, IL.

PUBLICATIONS

<https://www.webofscience.com/wos/author/record/891586>

These citation statistics refer only to articles and do not include abstracts.

Total Citations: >7,500. Average citations/publication: >75. i-100 = 22. i-50 = 49. i-25 = 67.

h-index: 49

I no longer record abstracts.

Full-length Publications:

1. Palazzo A J, **Jones S P**, Girod W G, Anderson D C, Granger D N, Lefer D J. Myocardial ischemia-reperfusion injury in CD18 and ICAM-1 deficient mice. 1998. *Am J Physiol.* 275: H2300–H2307. PMID: 9843832.
2. Palazzo A J, **Jones S P**, Anderson D C, Granger D N, Lefer D J. Coronary endothelial P-selectin in the pathogenesis of myocardial ischemia-reperfusion injury. 1998. *Am J Physiol.* 275: H1865–H1872. PMID: 9815095.
3. **Jones S P**, Girod W G, Palazzo A J, Jourd'heuil D, Grisham M B, Granger D N, Huang P L, Lefer D J. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. 1999. *Am J Physiol.* 276: H1567–H1573. PMID: 10330240.
4. Lefer D J, **Jones S P**, Girod W G, Baines A, Grisham M B, Cockrell A S, Huang P L, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase deficient mice. 1999. *Am J Physiol.* 276: H1943–H1950. PMID: 10362674.
5. **Jones S P**, Girod W G, Granger D N, Palazzo A J, Lefer D J. Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. 1999. *Am J Physiol.* 277: H763–H769. PMID: 10444504.
6. Girod W G, **Jones S P**, Sieber N, Aw T Y, Lefer D J. Effects of hypercholesterolemia on myocardial ischemia-reperfusion injury in LDL receptor deficient mice. 1999. *Arterioscler Thromb Vasc Biol.* 19: 2776–2781. PMID: 10559025.
7. Davis J, Gute D, **Jones S P**, Krsmanovic A, Korthuis R J. Ischemic preconditioning prevents postischemic P-selectin expression in the rat small intestine. 1999. *Am J Physiol.* 277: H2476–H2481. PMID: 10600871.
8. Hoffmeyer M R, **Jones S P**, Ross C R, Sharp B, Grisham M B, Laroux F S, Stalker T J, Scalia R, Lefer D J. Myocardial ischemia-reperfusion injury in NADPH oxidase deficient mice. 2000. *Circ Res.* 87: 812–817. PMID: 11055986.
9. **Jones S P**, Trocha S D, Strange M B, Granger D N, Kevil C G, Bullard D C, Lefer D J. Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. 2000. *Am J Physiol.* 279: H2196–H2201. PMID: 11045953.
10. Hoffmeyer M R, Scalia R, Ross C R, **Jones S P**, Lefer D J. PR-39, a potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice. 2000. *Am J Physiol.* 279: H2824–H2828. PMID: 11087237.
11. Bueno O F, De Windt L J, Tymitz K M, Witt S A, Kimball T R, Klevitsky R, Hewett T E, **Jones S P**, Lefer D J, Peng C-F, Kitsis R N, Molkentin J D. The MEK1 - ERK 1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. 2000. *EMBO J.* 19: 6341–6350. PMID: 11101507.
12. **Jones S P**, Girod W G, Huang P L, Lefer D J. Myocardial reperfusion injury in nNOS deficient mice. 2000. *Coron Art Dis.* 11: 593–597. PMID: 11107506.
13. **Jones S P**, Lefer D J. Myocardial reperfusion injury: Insights gained from gene-targeted mice (invited review). 2000. *News Physiol Sci.* 15: 303–308. PMID: 11390931.
14. **Jones S P**, Lefer D J. Using gene-targeted mice to investigate the pathophysiology of myocardial reperfusion injury (invited review). 2000. *Bas Res Cardiol.* 95: 499–502. PMID: 11192372.
15. **Jones S P**, Girod W G, Marotti K R, Cole P A, Aw T Y, Lefer D J. Acute exposure to a high cholesterol diet attenuates myocardial ischemia-reperfusion injury in cholesteryl ester transfer protein mice. 2001. *Coron Art Dis.* 12: 37–44. PMID: 11211164.
16. Scalia R, Gooszen M E, **Jones S P**, Hoffmeyer M, Rimmer III D M, Trocha S D, Huang P L, Smith M B, Lefer A M, Lefer D J. Simvastatin exerts both anti-inflammatory and cardioprotective effects in ApoE deficient mice. 2001. *Circulation.* 103: 2598–2603. PMID: 11382730.
17. Lefer D J, Scalia R, **Jones S P**, Sharp B R, Hoffmeyer M R, Farvid A R, Gibson M F, Lefer A M. Acute HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. 2001. *FASEB J.* 10: 1096/fj:00-0819fje. PMID: 11387255.
18. **Jones S P**, Trocha S D, Lefer D J. Pretreatment with simvastatin attenuates myocardial dysfunction following ischemia and chronic reperfusion. 2001. *Arterioscler Thromb Vasc Biol.* 21: 2059–2064. PMID: 11742885.

19. Condorelli G, Roncarati R, Ross J Jr, Pisani A, Stassi G, Todaro M, Trocha S, Drusco A, Gu Y, Russo M A, **Jones S P**, Lefer D J, Napoli C, Croce C M. Heart-targeted overexpression of *caspase3* in mice increases infarct size, sensitizes to adriamycin toxicity, and depresses cardiac function. 2001. *Proc Natl Acad Sci USA*. 98: 9977–9982. PMID: 11493678.
20. **Jones S P**, Lefer D J. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction (invited review). 2001. *Acta Physiol Scand*. 173: 139-144. PMID: 11678736.
21. Chang W-L, **Jones S P**, Lefer D J, Welbourne T, Sun G, Yin L, Bauer P, Huang J, Granger D N, van der Heyde H C. CD8+-T-cell depletion ameliorates circulatory shock in *Plasmodium berghei*-infected mice. 2001. *Infect Immun*. 69: 7341–7348.
22. **Jones S P**, Trocha S D, Lefer D J. Cardioprotective actions of endogenous IL-10 are independent of iNOS. 2001. *Am J Physiol*. 281: H48–H52. PMID: 11406467.
23. Sharp B R, **Jones S P**, Rimmer III D M, Lefer D J. Differential response to myocardial ischemia-reperfusion injury in endothelial nitric oxide synthase deficient mice. 2002. *Am J Physiol*. 282: H2422–H2426. PMID: 12003854.
24. **Jones S P**, Gibson M F, Rimmer III D M, Gibson T M, Sharp B R, Lefer D J. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. 2002. *J Am Coll Cardiol*. 40: 1172–1178. PMID: 12354446.
25. **Jones S P**, Hoffmeyer M R, Sharp B S, Ho Y-S, Lefer D J. Role of intracellular antioxidant enzymes after *in vivo* myocardial ischemia and reperfusion. 2003. *Am J Physiol*. 284: H277–H282. PMID: 12485820.
26. Akao M, O'Rourke B, Kusuoka H, Teshima Y, **Jones S P**, Marbán E. Differential actions of cardioprotective agents on the mitochondrial death pathway. 2003. *Circ Res*. 92: 195–202. PMID: 12574147.
27. **Jones S P**, Greer J J M, van Haperen R, Duncker D, de Crom R, Lefer D J. Increased endothelial nitric oxide synthase activity attenuates congestive heart failure in mice. 2003. *Proc Natl Acad Sci USA*. 100: 4891–4896. PMID: 12676984.
28. Yang J, **Jones S P**, Suhara T, Greer J J M, Ware P D, Nguyen N P, Perlman H, Nelson D P, Lefer D J, Walsh K. Endothelial cell overexpression of FasL attenuates ischemia-reperfusion injury in the heart. 2003. *J Biol Chem*. 278: 15185–15191. PMID: 12576484.
29. Teshima Y, Akao M, **Jones S P**, Marbán E. Cariporide (HOE642), a selective Na⁺-H⁺ exchange inhibitor, inhibits the mitochondrial death pathway. *Circulation*. 2003. 108: 2275–2281. PMID: 14568900.
30. **Jones S P**, Teshima Y, Akao M, Marbán E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. 2003. *Circ Res*. 93: 697–699. PMID: 14512440.
31. Teshima Y, Akao M, **Jones S P**, Marbán E. Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. 2003. *Circ Res*. 93: 192–200. PMID: 12855674.
32. **Jones S P**, Greer J J M, Kakkar A K, Ware P D, Turnage R H, Hicks M, van Haperen R, de Crom R, Kawashima S, Yokoyama M, Lefer D J. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. *Am J Physiol*. 2004. H276–H282. PMID: 12969888.
33. **Jones S P**, Greer J J M, Ware P D, Yang J, Walsh K, Lefer D J. Deficiency of iNOS does not attenuate severe congestive heart failure in mice. 2005. *Am J Physiol*. 288: H365–H370. PMID: 15319210.
34. Xue T, Cho H-C, Akar F G, Tsang S-Y, **Jones S P**, Tomaselli G F, Marbán E, Li R A. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: Insights into the development of cell-based pacemakers. 2005. *Circulation*. 111:11–20. PMID: 15611367. "Best Paper Award" - Basic Sciences 2005
35. **Jones S P**. A bittersweet modification: O-GlcNAc and cardiac dysfunction (editorial). 2005. *Circ Res*. 96: 925–926. PMID: 15890978.
36. **Jones S P**, Bolli R. The ubiquitous role of NO in cardioprotection (invited review). 2006. *J Mol Cell Cardiol*. 40: 16–23. PMID: 16288777.
37. Greer J J M, Kakkar A K, Elrod J W, Watson L J, **Jones S P**, Lefer D J. Low dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. 2006. *Am J Physiol*. 291: H2743–H2751. PMID: 16844920.
38. **Jones S P**, Zachara N E, Ngoh G A, Hill B G, Teshima Y, Bhatnagar A, Hart G W, Marbán E. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. 2008. *Circulation*. 117: 1172–1182. PMID: 18285568.
39. Wang Q, Donthi R V, Wang J, Watson L J, Lange A J, **Jones S P**, Epstein, P N. Cardiac phosphatase deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy and myocyte resistance to hypoxia. 2008. *Am J Physiol*. 294: H2889–H2897. PMID: 18456722.

40. Ngoh G A, Watson L J, Facundo H T, Dillmann W, **Jones S P**. Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. 2008. *J Mol Cell Cardiol.* 45: 313–325. [PMC2610867](#).
41. Deschênes I, Aroundas A A, **Jones S P**, Tomaselli G F. Post-transcriptional gene silencing of KChIP2 in cardiac myocytes suggests a structural and developmental link between I_{to} and Na channel. 2008. *J Mol Cell Cardiol.* 45: 336–346. [PMC2580777](#).
42. Ngoh G A, **Jones S P**. New insights into metabolic signaling and survival: The role of O-GlcNAc. (invited review). 2008. *J Pharmacol Exp Therap.* 327: 602–609. PMID: 18768779.
43. Ngoh G A, Facundo H T, Hamid T, Dillmann W, Zachara N E, **Jones S P**. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia. 2009. *Circ Res.* 104: 41–49. See associated editorial on pg. 7. [PMC2712829](#).
44. Facundo H T, **Jones S P**. AMPK Activators: Not Just for Diabetes? (editorial). 2009. *Circ Res.* 104: 282–284. [PMC2713438](#).
45. Ngoh G A, Hamid T, Prabhu S D, **Jones S P**. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. 2009. *Am J Physiol.* 297: H1711–1719. [PMC2781370](#).
46. Schaller S, Paradis S, Ngoh G A, Assaly R, Buisson B, Drouot C, Ostuni M A, Lacapere J-J, Bassissi F, Bordet T, Berdeaux A, **Jones S P**, Morin D, Pruss R M. TRO40303 (3,5-seco-4-nor-cholestan-5-one oxime-3-ol), a new in vitro and in vivo cardioprotective compound, inhibits mitochondrial permeability transition pore by targeting oxidative stress. 2010. *J Pharmacol Exper Therap.* 333: 696–706. PMID: 20215409.
47. Ngoh G A, Facundo H T, Zafir A, **Jones S P**. O-GlcNAc signaling in the cardiovascular system. 2010. *Circ Res.* 107: 171–185. [PMC2919351](#).
48. Watson L J, Facundo H T, Ngoh G A, Ameen M, Brainard R E, Lemma K M, Long B M, Prabhu S D, Xuan Y-T, **Jones S P**. O-GlcNAc transferase is indispensable in the failing heart. 2010. *Proc Nat Acad Sci USA.* 107: 17797–17802. [PMC2955091](#).
49. Ngoh G A, Watson L J, Facundo H T, **Jones S P**. Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. 2011. *Amino Acids.* 40: 895–911. *Focused issue on O-GlcNAc.* [PMC3118675](#).
50. Sansbury B E, Riggs D W, **Jones S P**, Hill B G. Responses of hypertrophied myocytes to reactive species: implications for glycolysis and electrophile metabolism. 2011. *Biochemical J.* 435: 519–528. [PMC4072126](#).
51. Sansbury B E, **Jones S P**, Riggs D W, Darley-Usmar VM, Hill B G. Bioenergetic function in cardiovascular cells: the importance of the reserve capacity and its biological regulation. 2011. *Chem Biol Interact.* 191: 288–295. [PMC3090710](#).
52. Wang J, Wang Q, Watson L J, **Jones S P**, Epstein P N. Cardiac overexpression of 8-oxoguanine DNA glycosylase 1 protects mitochondrial DNA and reduces cardiac fibrosis following transaortic constriction. 2011. *Am J Physiol Heart Circ Physiol.* 301: H2073–H2080. [PMC3213972](#).
53. Guo Y, Tukaye D N, Wu W-J, Zhu X, Tan W, **Jones S P**, Rokosh G, Narumiya S, Li Q, Bolli R. The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning. 2012. *PLoS ONE.* 7: e41178. [PMC3402528](#).
54. Facundo H T, Brainard R E, Watson L J, Ngoh G A, Hamid T, Prabhu S D, **Jones S P**. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. 2012. *Am J Physiol Heart Circ Physiol.* 302: H2122–H2130. [PMC3362113](#). *Focus of an AJP Podcast.*
55. Readnower R, Brainard R E, Hill B G, **Jones S P**. Standardized bioenergetic profiling of adult mouse cardiomyocytes. 2012. *Physiol Genomics.* 44: 1208–1213. [PMC3544486](#).
56. Wang J, Xu J, Wang Q, Brainard R E, Watson L J, **Jones S P**, Epstein P N. Reduced cardiac fructose 2,6-bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction. 2013. *PLoS ONE.* 8: e53951. [PMC3538739](#).
57. Li M-D, Ruan H-B, Hughes M E, Lee J-S, Singh J P, **Jones S P**, Nitabach M N, Yang X. O-GlcNAc signaling entrains the circadian clock by modulating BMAL1/CLOCK ubiquitination. 2013. *Cell Metab.* 17: 303–310. [PMC3647362](#).
58. Zafir A, Readnower R D, Long B W, McCracken J, Aird A, Alvarez A, Li Q, Hill B G, Bhatnagar A, Prabhu S D, Bolli R, **Jones S P**. Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. 2013. *Stem Cells.* 31:765–775. [PMC3606688](#).
59. Salabei J K, Cummins T D, Singh M, **Jones S P**, Bhatnagar A, Hill B G. PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. 2013. *Biochem J.* 451: 357–388. [PMC4040966](#).

60. Brainard R E, Watson L J, DeMartino A M, Brittian K R, Readnower R D, Boakye A A, Zhang D, Hoetker J D, Bhatnagar A, Baba S P, **Jones S P**. High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. 2013. *PLoS ONE*. 8:e83174. [PMC3867436](#).
61. Watson L J, Long B E, DeMartino A M, Brittian K R, Readnower R D, Brainard R E, Annamalai L, Hill B G, **Jones S P**. Cardiomyocyte *Ogt* is essential for postnatal viability. 2014. *Am J Physiol Heart Circ Physiol*. 306: H142–153. [PMC3920156](#).
62. Dassanayaka S, **Jones S P**. O-GlcNAc and the cardiovascular system. 2014. *Pharmacology and Therapeutics*. 142: 62–71. [PMC3943723](#).
63. Sansbury B E, De Martino A M, Xie Z, Brooks A C, Brainard R E, Watson L J, DeFilippis A P, Cummins T D, Harbeson M A, Brittian K R, Prabhu S D, Bhatnagar A, **Jones S P**, Hill B G. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. 2014. *Circ Heart Fail*. 7: 634–642. [PMC4102656](#).
64. Leucker T M, **Jones S P**. Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication. *Frontiers in Physiology*. 2014. 5: 328. [PMC4144117](#).
65. Muthusamy S, De Martino A M, Watson L J, Brittian K R, Zafir A, Dassanayaka S, Hong K U, **Jones S P**. miR-539 is upregulated during heart failure, and suppresses O-GlcNAcase expression. 2014. *J Biol Chem*. 289: 29665–29676. [PMC4207981](#).
66. **Jones S P**, Tang X L, Guo Y, Steenbergen C, Lefer D J, Kukreja R C, Kong M, Li Q, Bhushan S, Zhu X, Book M, Du J, Nong Y, Stowers H L, Kondo K, Hunt G N, Goodchild T T, Orr A, Chang C C, Ockaili R, Salloum F N, Bolli R. Establishment and validation of a preclinical, multicenter, multispecies consortium for the assessment of infarct size-reducing agents: CAESAR (Consortium for the preclinical assessment of cardioprotective therapies). 2015. *Circ Res*. 116: 572–586. [PMC4329104](#).
67. Dassanayaka S, Readnower R D, Long B W, Aird A L, Salabei J K, Facundo H T, Hill B G, **Jones S P**. High glucose induces mitochondrial dysfunction independent of protein O-GlcNAcylation. 2015. *Biochemical J*. 467: 115–126. [PMC4408906](#).
68. Brooks A C, DeMartino A M, Brainard R E, Brittian K R, Bhatnagar A, **Jones S P**. Induction of activating transcription factor 3 limits survival following infarct-induced heart failure in mice. 2015. *Am J Physiol Heart Circ Physiol*. 309: H1326–1335. [PMC4666961](#).
69. Dassanayaka S, **Jones S P**. Recent developments in heart failure. 2015. *Circ Res*. 117: e58–63. [PMC4574505](#).
70. Zafir A, Bradley J A, Long B W, Muthusamy S, Li Q, Hill B G, Wysoczynski M, Prabhu S D, Bhatnagar A, Bolli R, **Jones S P**. O-GlcNAcylation negatively regulates cardiomyogenic fate in adult mouse cardiac mesenchymal stromal cells. 2015. *PLoS ONE*. 10: e0142939. [PMC4643874](#).
71. Muthusamy S, Hong K U, Dassanayaka S, Hamid T, **Jones S P**. E2F1 transcription factor negatively regulates O-GlcNAc transferase and O-GlcNAcase expression. 2015. *J Biol Chem*. 290: 31013–31024. [PMC4692227](#).
72. Wysoczynski M, Dassanayaka S, Zafir A, Ghafghazi S, Long BW, Noble C, DeMartino AM, Brittian KR, Bolli R, **Jones S P**. A new method to stabilize c-kit expression in reparative cardiac mesenchymal cells. 2016. *Front Cell Dev Biol*. 4:78. doi: 10.3389/fcell.2016.00078. [PMC4971111](#).
73. Hamid T, Ma Y, Ismahil M A, Li Q, **Jones S P**, Bhatnagar A, Bolli R, Prabhu S D. TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate. 2016. *Am J Physiol Heart Circ Physiol*. 311: H1189–H1201. [PMC5130488](#).
74. Kingery J R, Hamid T, Lewis R K, Ismahil M A, Bansal S S, Ildstad S T, **Jones S P**, Prabhu S D. Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure. 2017. *Basic Res Cardiol*. 112: 19. [PMC5555149](#).
75. Dassanayaka S, Brainard R E, Watson L J, Long B W, Brittian K R, DeMartino A M, Aird A M, Gumpert A M, Audam T N, Kilfoil P J, Muthusamy S, Hamid T, Prabhu S D, **Jones S P**. Cardiomyocyte *Ogt* limits ventricular dysfunction following pressure overload without affecting hypertrophy. 2017. *Basic Res Cardiol*. 112: 23. [PMC5555162](#).
76. **Jones S P**. I'll have the rigor but hold the mortis (editorial). 2017. *Circ Res*. 120: 1852–1854. [PMC5505656](#).
77. Zucker I H, Lindsey M L, Delmar M, De Windt L J, Des Rosiers C, Diz D I, Hester R L, **Jones S P**, Kanagy N L, Kitakaze M, Liao R, Lopaschuk G D, Patel K P, Recchia F A, Sadoshima J, Shah A M, Ungvari Z, Benjamin I J, Blaustein M P, Carkoudian N, Efimov I R, Gutterman D, Kass D A, Liao Y, O'Leary D, Ripplinger C, Wolin M S. Why publish in *AJP-Heart and Circulatory Physiology*? 2017. *Am J Physiol Heart Circ Physiol*. 313:H221–H223. PMID: N/A.

78. Gibb A A, Lorkiewicz P K, Zheng Y-T, Zhang X, Epstein P N, Bhatnagar A, **Jones S P**, Hill B G. Integration of flux measurements to resolve changes in anabolic and catabolic metabolism in cardiac myocytes. 2017. *Biochemical J*. 474: 2785–2801. PMID: [PMC5545928](#).
79. Gibb A A, Epstein P N, Uchida S, McNally L A, Zheng Y, Obal D, Katragadda K, Conklin D J, Brittian K R, Tseng M, Wang J, **Jones S P**, Bhatnagar A, Hill B G. Exercise-induced changes in glucose metabolism promote physiologic cardiac growth. 2017. *Circulation*. 136:2144–2157. PMID: [PMC5704654](#).
80. Uchida S, **Jones S P**. Unexplored opportunities in the cardiovascular system. 2018. *Circ Res*. 122: 399–401. PMID: [PMC5808601](#).
81. Lindsey M L, Bolli R, Canty J, Du X-J, Frangogiannis N G, Frantz S, Gourdie R, Holmes J W, **Jones S P**, Kloner R A, Lefer D J, Liao R, Murphy E, Ping P, Przyklenk K, Recchia F, Schwartz-Longacre L, Ripplinger C M, Van Eyk J, Heusch G. Guidelines for experimental models of myocardial ischemia and infarction. 2018. *Am J Physiol Heart Circ Physiol*. 314: H812–H838. PMID: [PMC5966768](#).
82. Hosen M R, Militello G, Weirick TM, Ponomareva Y, Dassanayaka S, Moore JB, Doering C, Wysoczynski M, **Jones S P**, Dimmeler S, Uchida S. *Airn* regulates Igf2bp2 translation in cardiomyocytes. 2018. *Circ Res*. 122:1347–1353. PMID: [PMC5948151](#).
83. Baba S P, Zhang D, Singh M, Dassanayaka S, Thomas J, Jagatheesan G, Conklin D J, Brittian K R, **Jones S P**, Bhatnagar A. Deficiency of aldose reductase exacerbates early pressure overload-induced cardiac dysfunction and autophagy in mice by preventing removal of lipid peroxidation products. 2018. *J Mol Cell Cardiol*. 118: 183–192. PMID: [PMC6205513](#).
84. Dassanayaka S, Yuting Z, Gibb A A, Cummins T D, McNally L A, Brittian K R, Jagatheesan G, Audam T N, Long B W, Brainard R E, **Jones S P**, Hill B G. Cardiac-specific overexpression of aldehyde dehydrogenase 2 exacerbates cardiac remodeling in response to pressure overload. 2018. *Redox Biology*. 17: 440–449. PMID: [PMC5991908](#).
85. Dassanayaka S, Brittian K R, Jurkovic A, Higgins L A, Audam T N, Long B W, Harrison L T, Militello G, Riggs D W, Chitre M, Uchida S, Muthusamy S, Gumpert A, and **Jones S P**. *E2f1* deletion attenuates infarct-induced ventricular remodeling without affecting O-GlcNAcylation. 2019. *Basic Res Cardiol*. 114: 29. [PMC7278029](#).
86. Metzler M A, Friedl R M, Raja S, Patel N, Brittian K R, **Jones S P**, Sandell L L. RDH10 function is necessary for spontaneous fetal mouth movement that facilitates palate shelf elevation. 2019. *Dis Model Mech*. 12: 7. [PMC6679383](#).
87. Ou Q, Jacobson Z, Abouleisa R, Tang X-L, Hindi S, Kumar A, Ivey K, Giridharan G, Al-Baz A, Brittian KR, Rood B, Hill B G, **Jones S P**, Terracciano CM, Bolli R, Mohamed TA. Physiological biomimetic culture system for pig and human heart slices. 2019. *Circ Res*. 125: 628–642. [PMC6715512](#).
88. Kilfoil P J, Chapalamadugu K C, Raucci F J, Tur J, Brittian K R, **Jones S P**, Bhatnagar A, Tipparaju S M, Nystoriak M A. Metabolic regulation of Kv channels and cardiac repolarization by Kv β 2 subunits. 2019. *J Mol Cell Cardiol*. 137: 93–106. [PMC7344177](#).
89. Hammouda K, Khalifa F, Abdeltawab H, Zhu M, Giridharan G A, Dassanayaka S, *Mohamed T M A, ***Jones S P**, *El-Baz A. A new framework for performing cardiac strain analysis from cine MRI imaging in mice. 2020. *Sci Rep*. 10: 7725. *co-corresponding authors. [PMC7205890](#).
90. Audam T N, Nong Y, Tomlin A, Jurkovic A, Li H, Zhu X, Long B W, Zheng Y W, Weirick T, Brittian K R, Riggs D W, Gumpert A, Uchida S, Guo Y, Wysoczynski M, **Jones S P**. Cardiac mesenchymal cells from failing hearts limit ventricular dilation when administered late after infarction. 2020. *Am J Physiol Heart Circ Physiol*. 319: H109–H122. [PMC7474443](#).
91. Dassanayaka S, Brittian K R, Long B W, Higgins L A, Audam T N, Jurkovic A, Gumpert A M, Harrison L T, Hartyánszky I, Perge P, Merkely B, Radovits T, Hanover J A, and **Jones S P**. Cardiomyocyte *Oga* haploinsufficiency increases O-GlcNAcylation but hastens ventricular dysfunction following myocardial infarction. 2020. *PLoS One*. 15: e0242250. [PMC7703924](#).
92. Alcaide P, **Jones S P**. The sweet smell of progress with hyaluronan and heart failure. 2021. *Hypertension*. 77: 1928–1930. [PMC8415039](#).
93. **Jones S P**. Angiotensinogen takes some of the spotlight from angiotensin II in the cardiohepatic axis. 2021. *Circ Res*. 129: 565–567. [PMC8384130](#).
94. Audam T N, Howard C M, Garrett L F, Zheng Y W, Bradley J A, Brittian K R, Frank M W, Fulghum K L, Pólos M, Herczeg S, Merkely B, Radovits T, Uchida S, Hill B G, Dassanayaka S, Jackowski S, **Jones S P**. Cardiac PANK1 deletion exacerbates ventricular dysfunction during pressure overload. 2021. *Am J Physiol Heart Circ Physiol*. 321: H784–H797. [PMC8794231](#).
95. Lindsey M L, Brunt K R, Kirk J A, Kleinbongard P, Calvert J W, de Castro Brás L E, DeLeon-Pennell K Y, Del Re D P, Frangogiannis N G, Frantz S, Gumina R J, Halade G V, **Jones S P**, Ritchie R H, Spinale F G,

- Thorp E B, Ripplinger C M, Kassiri Z. Guidelines for *in vivo* mouse models of myocardial infarction. 2021. *Am J Physiol Heart Circ Physiol*. 321: H1056–H1073. [PMC8834230](#).
96. Zelko I N, Dassanayaka S, Malovichko M V, Howard C M, Garrett L F, Uchida S, Brittian K R, Conklin D J, **Jones S P**, Srivastava S. Chronic benzene exposure aggravates pressure overload-induced cardiac dysfunction. 2022. *Toxicological Sciences*. 185: 64–76. [PMC8714365](#).
97. Sadri G, Fischer A G, Elliott E, Brittian K R, Nystoriak M A, Uchida S, Wysoczynski M, Leask A, **Jones S P**, Moore J B IV. Collagen type XIX regulates cardiac extracellular matrix structure and ventricular function. 2022. *Matrix Biology*. 109: 49–69. [PMC9161575](#).
98. Fulghum K L, Collins H E, **Jones S P**, Hill B G. Influence of biological sex and exercise on murine cardiac metabolism. 2022. *Journal of Sport and Health Science*. 11: 479–494. [PMC9338340](#).
99. Fulghum K L, Smith J B, Chariker J, Garrett L F, Brittian K R, Lorkiewicz P, McNally L A, Uchida S, **Jones S P**, Hill B G, Collins H E. Metabolic signatures of pregnancy-induced cardiac growth. 2022. *Am J Physiol Heart Circ Physiol*. 323: H146–H164. [PMC9236881](#).
100. Head K Z, Bolatimi O E, Gripshover T C, Tan M, Li Y, Audam T N, **Jones S P**, Klinge C M, Cave M C, Wahlang B. Investigating the effects of long-term Aroclor 1260 exposure on fatty liver disease in a diet-induced obesity mouse model. 2023. *Frontiers*. In press.

Book Chapters

- Jones S P**, Lefer D J. Leukocyte-endothelial interactions following myocardial ischemia. In: *Molecular Basis for Microcirculatory Disorders*. G W Schmid-Schönbein & D N Granger (eds). 2002.